Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for …

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.

“We are very pleased with the progress to date in our ongoing strategic collaboration with Merck,” said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. “Extending the research term of our agreement based on promising preclinical data with a goal of identifying a clinical candidate underscores the significant potential of our therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and CUE-300 series in the treatment of debilitating

Read More

Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.

“We are very pleased with the progress to date in our ongoing strategic collaboration with Merck,” said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. “Extending the research term of our agreement based on promising preclinical data with a goal of identifying a clinical candidate underscores the significant potential of our therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and CUE-300 series in the treatment of debilitating

Read More

French drugmaker Sanofi has just invested $59 million in biotech investor Jeito Capital to fund innovation in the biopharma pipeline



logo: FILE PHOTO: Sanofi logo is seen in Paris Reuters


© Reuters
FILE PHOTO: Sanofi logo is seen in Paris Reuters

  • Sanofi, one of the world’s biggest pharmaceutical companies, has invested €50 million in new French-based VC Jeito Capital.
  • Jeito CEO Rafaèle Tordjman, managing director of innovation at Jeito Capital, spoke with Business Insider about how the fund plans to invest the money.
  • Jeito’s first fund has already invested in two companies, with plans to invest in a further 4-5 in the next year.
  • Visit Business Insider’s homepage for more stories.

France’s Sanofi, one of the world’s biggest pharmaceutical companies, has invested €50 million ($59 million) in venture capital firm Jeito Capital, Jeito CEO Rafaèle Tordjman said on Friday.

Loading...

Load Error

Jeito Capital, a Paris-based venture capital firm, plans to invest in biopharma and biotech companies across all different funding stages. Sanofi is the world’s fifth-largest drugmaker by prescription sales. Its better known over-the-counter brands include anti-acid products such as

Read More